TP53 and acute myeloid leukemia: There have also been proposals to introduce a fourth ‘very-adverse-risk group’ that include TP53 Mut AML and selected cytogenetic aberrations based on the observed clinical outcomes that are distinctly worse when compared to other genotypes in the ELN 2022 adverse-risk group.